CRT Pioneer fund, BACIT and SAREUM agree to cancer drug funding
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
List view / Grid view
News
New Phase III data showed Dapagliflozin significantly reduced HbA1c compared to placebo
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
GSK receives marketing authorisation from the European Commission for additional Revolade™ (eltrombopag) indication
25 September 2013 | By GSK
European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection...
Enrolment of Victoza® (liraglutide) cardiovascular outcomes trial completed on schedule
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
Amgen And ShanghaiTech University announce plans for R&D center
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
Pfizer announces data for XELJANZ® (tofacitinib citrate) in rheumatoid arthritis
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
AbbVie and Galapagos to co-develop Cystic Fibrosis therapies
25 September 2013 | By AbbVie
Global alliance formed to discover, develop and commercialise novel potentiator and combination therapies in cystic fibrosis...
Latest Phase 3 Results demonstrate safety profile of INVOKANA® (canagliflozin) as add-on therapy in the treatment of Type 2 Diabetes
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
Takeda receives European marketing authorisation for three new type 2 diabetes therapies
24 September 2013 | By Takeda
Authorisation received for VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) and IncresyncTM (alogliptin and pioglitazone)...
FDA imposes import ban on Ranbaxy’s Mohali plant
24 September 2013 | By Daiichi Sankyo Company, Limited
Ranbaxy Laboratories has received communication from the FDA about an Import Alert imposed on its Mohali, India, plant following an inspection in late 2012...
Paul Marks Prize 2013 awarded to Cancer Research UK scientist
23 September 2013 | By Cancer Research UK
Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America...
Teva announces favorable court ruling in AZILECT® patent infringement litigation against Mylan
23 September 2013 | By Teva
The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.
Merck receives complete response letter for investigational medicine Sugammadex Sodium Injection
23 September 2013 | By Merck
Merck has received a Complete Response Letter from the FDA for the resubmission of the New Drug Application for sugammadex sodium injection, Merck’s investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium...
Roche to share important oncology data at European Cancer Congress (ECC)
23 September 2013 | By Roche
Data for established therapies Avastin, Herceptin, Kadcyla and Zelboraf amongst highlights...
